Saturday, June 25, 2022
News

Cellular exosomes might improve delivery of anticancer drugs to tumours: Research

   SocialTwist Tell-a-Friend    Print this Page   COMMENT

Glasgow | April 25, 2022 12:53:38 AM IST
Exosomes or small bubbles that transport molecules from one cell to another can be effective vehicles for delivering cancer treatments to tumours, according to a recent study.

The findings of the study were published in the journal, 'Cancer Medicine'.

The study was led by researchers from the University of Glasgow, Griffith University, and Yale University.

In the study, researchers used exosomes produced by cells called adipose-derived mesenchymal stem cells (ADSCs) to deliver an RNA-based anti-cancer treatment (miR-138-5p) to bladder cancer tumours in mice.

"The present results reveal that ADSC-derived exosomes are an effective delivery vehicle for small molecule drugs in vivo, and exosome-delivered miR-138-5p is a promising therapeutic agent for bladder cancer treatment," the authors wrote. (ANI)

 
  LATEST COMMENTS ()
POST YOUR COMMENT
Comments Not Available
 
POST YOUR COMMENT
 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
 
MORE HEALTH NEWS
Breast cancer spreads during sleep, sugg...
Scientists show elevated leptin levels i...
Study: Plant-based substitutes provide l...
Delhi Covid cases drop to 1,447, one mor...
Delhi HC allows doctor in vacant seat of...
Explained: What's driving Covid surge in...
More...
 
INDIA WORLD ASIA
Woman in illicit affair lured and killed...
Gujarat government did not delay calling...
One held in Edakkara Maoist case: NIA...
Jalalabad IED blast: NIA searches multip...
Saradha chit fund promoter accuses Suven...
Mukesh Ambani donates Rs 25cr towards As...
More...    
 
 Top Stories
Walking might improve cognitive tas... 
Archery WC Paris: Abhishek Verma, J... 
Breast cancer spreads during sleep,... 
Shehnaaz Gill looks like a fresh br... 
Shiv Sena traditionally rivals of N... 
Ill-treatment of Uyghurs by China t... 
Microbiomes of people and homes the... 
Turkey's concerns not eased on Finl...